

## Official Air Force Ground Based Operator (GBO) Approved Medications

**Quick Reference List** 

Effective: 10 May 2022

(Note: Ground Based Operator Medications list shall be reviewed prior to initiation of new medications; this list supersedes the GBO medication list dated 1 February 2022)

This Approved Medication List applies to Missile Operators (MOD, 13N) RPA Pilots (11UX) after they have completed Undergraduate RPA Training (URT) and are operating solely from the ground, and RPA Sensor Operators (1U0X1), which collectively be known as Ground Based Operators (GBO) for the purpose of medical standards and this medication list.

The approved medication list consists of drugs for acute and chronic conditions, listed by generic name under one of three categories, based on whether they may be prescribed without DOWN, may be prescribed by the flight surgeon without a waiver, or require a waiver. At the end of the document are listed a number of drugs which are known to be unacceptable for GBO. Request for waiver of such drugs is highly unlikely.

A large number of FDA-approved prescription drugs are not listed under either section. If such drugs are used for acute conditions, it should be assumed that the drug is disqualifying for GBO duty, with the GBO member returning to alert/controlling status after the condition has resolved, the medication has been discontinued, and its effects have dissipated, which usually entails one additional day (the "24-hour rule"). For chronic conditions, most common conditions are treatable by one or more of the listed drugs, and use of these drugs is likely to receive favorable consideration and a more expeditious result. If the GBO member is intolerant of or inadequately controlled by a listed medication, but is successfully treated by a non-listed drug, a waiver request for that drug may be submitted through MAJCOM/SGP to AFMRA. Such requests are not delegated for initial or renewal waivers. All medications and immunizations use by GBO personnel must be FDA vetted. For Over the Counter (OTC) Medications, FDA-approved OTC medications and commercially available (in the United States) substances, to include herbal and nutritional supplements, may generally be used by GBO personnel without flight surgeon approval, provided the product is used in accordance with manufacturers' directions for its intended use and not in violation of Air Force policy. GBO personnel are required to consult with the flight surgeon whenever: the member is within 12 hours of reporting for GBO and will be using the product for the very first time; or member experiences adverse reactions which may affect the member's ability to perform GBO.

Members pending waiver action must be DOWN until waiver has been granted. Verbal waivers are NOT authorized. Consult Aerospace Medicine Waiver Guide prior to waiver submission. Waivers for non-FDA approved medications will not be considered.

Note that while a specific drug may be acceptable without waiver, the treated condition may still require waiver.

## **SUMMARY OF CHANGES:**

1. Removed topiramate 2. Calcium channel blockers for headache and hypertension clarified.

| Category           | Medic  | Medication  |   | Diagnosis No                   |                        | N status<br>er Required)             |                                  |  |
|--------------------|--|---|---|--------------------------------|------------------------|--------------------------------------|----------------------------------|--|
| 5.00 <b>5</b> 00 5 | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise) | Trade Name (Not<br>Inclusive)                               | or<br>Utilization   | DOWN<br>status<br>Or<br>Waiver | For<br>Ground<br>Trial | Symptoms Controlled (No Side Effect) | DOWN status<br>(Waiver Required) | Notes  |
| Card               | ACE Inhibitors   | Lotensin, Capoten,<br>Vasotec, Monopril,<br>Zestril, Altase | Hypertension  |                                |                        | X                                    |                                  | For use as a single agent or in combination with other approved antihypertensive. DOWN for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DOWN period. |
| Gen                | Acetaminophen  | Tylenol   | Pain (Acute Use)  | X                              |                        |                                      |                                  | DOWN is not required for occasional OTC use to provide relief from minor self-limiting conditions.   |
| Gen                | Acetaminophen  | Tylenol   | Pain (chronic use)  |                                |                        | X                                    |                                  | DOWN until potential for idiosyncratic reaction has been ruled out and pain/inflammation control is achieved.  |
| Gen                | Acupuncture  | Seirin needle,<br>ASP needle                                | Pain (acute condition use)  | X                              |                        |                                      |                                  | Minimum of 2 hours ground trial at initiation of therapy to  |
| Gen                | Acupuncture  | Seirin needle,<br>ASP needle                                | Pain (chronic use)  | X                              |                        |                                      |                                  | ensure idiosyncratic reaction is ruled out. After initial ground trial, no DOWN required unless underlying condition interferes with GBO duties.   |
| Gen                | Acupuncture  | Seirin needle,<br>ASP needle                                | Chronic medical<br>condition (i.e.<br>PTSD, OA)   | X                              |                        |                                      |                                  | Auricular ASP needles may be retained during GBO duty performance.   |
| Derm               | Acyclovir  | Zovirax   | HSV (Treatment and Suppression)   |                                | X                      |                                      |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |
| Derm               | Acyclovir<br>(Topical)   | Zovirax<br>(Topical)  | HSV   | X                              |                        |                                      |                                  | DOWN not required unless condition or medication interferes duties.  |
| Gen                | Adalimumab   | Humira  | Reactive Arthritis/<br>Rheumatoid<br>Arthritis/<br>Psoriasis and<br>Psoriatic Arthritis/<br>Ankylosing<br>Spondylitis/<br>Ulcerative Colitis*,<br>Crohns* |                                |                        |                                      | X                                | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Restricted Deployability, see Waiver Guide. Adalimumab Background Paper  *Consult Waiver Guide for use in IBD patients.   |
| Derm               | Adapalene<br>0.1% Gel<br>(topical)                               | Differin  | Acne Vulgaris   | X                              |                        |                                      |                                  | DOWN not required unless condition or medication interferes with GBO duties. <u>Adapalene Background Paper</u>   |
| Pulm               | Albuterol  | Proventil   | Asthma  |                                |                        |                                      | X                                | Requires IRILO/MEB submission prior to waiver.   |
| MS                 | Alendronate  | Fosamax   | Osteoporosis<br>(Prophylaxis and<br>Treatment)  |                                | X                      |                                      |                                  | DOWN until potential for idiosyncratic reaction has been ruled out and patient tolerates medication well. Take on non-alert days, if possible, or with food at least 30 minutes before duty.   |

| Category   | Medic   | Medication                                      |   | Diagnosis No                   |                        | N status<br>er Required)                      |                                  |  |
|------------|---|---|---|--------------------------------|------------------------|---|----------------------------------|--|
| Category   | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise)        | Trade Name (Not<br>Inclusive)                   | or<br>Utilization                           | DOWN<br>status<br>Or<br>Waiver | For<br>Ground<br>Trial | Symptoms<br>Controlled<br>(No Side<br>Effect) | DOWN status<br>(Waiver Required) | Notes  |
| GU         | Alfuzosin   | Uroxatral                                       | ВРН   |                                |                        |   | X                                | Max dose 10 mg daily. Rapaflow is first line agent and does not require waiver.  See Alfuzosin Paper.  |
| MS         | Allopurinol   | Zyloprim  | Gout and<br>Urolithiasis                    |                                |                        | X   |                                  | For urolithiasis either alone or in combination with thiazide (hydrochlorothiazide or chlorothiazide).   |
| Derm       | Aluminum Chloride<br>Hexahydrate  | Drysol  | Hyperhidrosis                               |                                |                        | Х   |                                  | For hyperhidrosis. DOWN until the underlying symptoms will not interfere with flying duties and there are no adverse side effects.   |
| Infect     | Amantadine  | Symmetrel                                       | Antiviral use only                          |                                |                        | Х   |                                  | DOWN until the potential for idiosyncratic reaction has been ruled out and underlying condition does not interfere with duties.  |
| Gen        | Anesthetic Agents<br>(Local or Regional)                                |   | Surgical<br>Procedures/Dental<br>Procedures |                                |                        | Х   |                                  | DOWN for at least 8 hours after receiving a local or regional anesthetic agent. Verbal DOWN and automatic return to status after 8 hours is authorized. Re-examination and return to status 2992 not required unless unexpected side-effects or complications occur.                 |
| Card       | Angiotensin Receptor<br>Blocker (ARB)                                   | Atacand, Avapro,<br>Cozaar, Micardis,<br>Diovan | Hypertension                                |                                |                        | X   |                                  | For use as a single agent or in combination with other approved antihypertensive. DOWN for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100.  |
| Card       | ARB + Calcium<br>Channel Blocker  |   | Hypertension                                |                                |                        | X   |                                  | For use as a single agent or in combination with other approved antihypertensive. DOWN for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DOWN period. |
| Card       | ARB + Diuretic  |   | Hypertension                                |                                |                        | X   |                                  | For use as a single agent or in combination with other approved antihypertensive. DOWN for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DOWN period. |
| Infections | Antibiotics (All oral, topical, otic and ophthalmic except Minocycline) |   | Acute or chronic infection                  |                                |                        | X   |                                  | DOWN until the potential for idiosyncratic reaction has been ruled out and underlying condition does not interfere with duties. Chronic underlying condition my require waiver.  |
| Derm       | Antibiotics (Topical)   |   | Acne  | X                              |                        |   |                                  | DOWN not required unless condition or medication interferes with GBO duties.   |
| Derm       | Antifungals (Topical)   |   | Dermatomycosis                              | X                              |                        |   |                                  | DOWN not required unless condition or medication interferes with duties.   |
| Infections | Antiparasitic   | Albenza, Vermox                                 |   |                                |                        | X   |                                  | DOWN for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out.  |

| Category | Medication   |   | Diagnosis No                                      | No                             |                        | VN status<br>ver Required)                    |                                  |  |
|----------|--|---|---|--------------------------------|------------------------|---|----------------------------------|--|
| Category | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise) | Trade Name (Not<br>Inclusive)                     | Utilization                                       | DOWN<br>status<br>Or<br>Waiver | For<br>Ground<br>Trial | Symptoms<br>Controlled<br>(No Side<br>Effect) | DOWN status<br>(Waiver Required) | Notes  |
| Derm     | Antiseptics (Topical)  |   | Acute Injury                                      | X                              |                        |   |                                  | DOWN not required unless condition or medication interferes with duties.   |
| Gen      | Aspirin  | Ecotrin   | Pain  | X                              |                        |   |                                  | DOWN is not required for occasional OTC use to provide relief from minor self-limiting conditions.   |
| Gen      | Aspirin  | Bayer Aspirin                                     | Prophylaxis                                       |                                | X                      |   |                                  | Single ground trial is required for members who have never previously taken aspirin; 81 mg or 325 mg once daily for prophylactic therapy as clinically indicated. Underlying disqualifying condition (when present) continues to require waiver.   |
| Gen      | Atovaquone/<br>Proguanil<br>(Combination)                        | Malarone  | Malaria<br>Prophylaxis<br>(2 <sup>nd</sup> Line)  |                                | X                      |   |                                  | Single dose ground trial required; Malarone (250 mg atovaquone/100 mg proguanil) daily beginning 1-2 days prior to travel; ending 7 days after exposure (Reminder: last 7 days of Malarone should be taken with primaquine followed by another 7 days of primaquine alone);  Malarone Background Paper.              |
| ENT      | Azelastine   | Astelin<br>Optivar                                | Vasomotor Rhinitis<br>Allergic-<br>Conjunctivitis |                                |                        | X   |                                  | Third line agent, trial of nasal steroid and Claritin/Allegra first. Minimum 72 hours ground trial at initiation of therapy and adequate control of rhinitis is required.  |
| Derm     | Benzyl Peroxide<br>(Topical)                                     |   | Acne  | X                              |                        |   |                                  | DOWN not required unless condition or medication interferes with duties.   |
| Card     | Betablockers   | Tenormin,<br>Lopressor, Inderal,<br>Toprol, Coreg | Hypertension                                      |                                |                        | X   |                                  | For use as a single agent or in combination with other approved antihypertensive. DOWN for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DOWN period.                                 |
| Card     | Betablockers   | Tenormin,<br>Lopressor, Inderal,<br>Toprol, Coreg | Headaches   |                                |                        |   | X                                | For use as a single agent or in combination with other approved antihypertensive. DOWN for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DOWN period.                                 |
| Ophthal  | Betaxolol Drops  | Betoptic  | Glaucoma  |                                |                        | X   |                                  | DOWN until potential for idiosyncratic reaction has been ruled out. Underlying condition may require waiver in which case, DOWN until waiver approved.   |
| Derm     | Botulinum Toxin A  | ВоТох   | Hyperhidrosis,<br>cosmetic purposes               |                                |                        | X   |                                  | Only approved for use in <u>axillary</u> hyperhidrosis, cosmetic purposes.  DOWN for 7 days monitoring time period. RTCS if the member tolerates the medication and symptom improvement noted.  Use for palmar hyperhidrosis and other non-cosmetic purposes is not approved, and requires ACS review/AFMRA approval |
| Psych    | Buproprion   | Wellbutrin<br>SR or XL                            | Waiverable Mental<br>Health Diagnoses             |                                |                        |   | X                                | Max dose 450 mg/day. Waiver will not be considered until member is on medication with stable dose and clinically asymptomatic for at least six months.   |

| Category  | Medic  | Medication   |   | Diagnosis No                   |                        | N status<br>er Required)             | - DOWN status     |   |
|-----------|--|--|---|--------------------------------|------------------------|--------------------------------------|-------------------|---|
|           | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise) | Trade Name (Not<br>Inclusive)  | or<br>Utilization                           | DOWN<br>status<br>Or<br>Waiver | For<br>Ground<br>Trial | Symptoms Controlled (No Side Effect) | (Waiver Required) | Notes   |
| Gen       | Bupropion  | Zyban  | Smoking Cessation                           |                                | X                      |                                      |                   | Two week ground trial to evaluate for irritability/aggression, attention deficit, SI/HI, seizure, sleep, and any cardiac side effects. Encourage alcohol abstinence to prevent seizures and completion of 90 minute tobacco cessation (online or in person) program to maximize efficacy.  *Must screen for depression when used for this indication. Follow Wellbutrin waiver requirements if Zyban is used >12 weeks. |
| Card      | Calcium Channel<br>Blockers                                      | Norvasc, Plendil,<br>Cardene, Adalat,<br>Procardia, Cardizem,<br>Calan | Headaches                                   |                                |                        | X                                    | X                 | DOWN for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out. A dose adjustment also requires a 7 day DOWN period.  |
| Card      | Calcium Chanel<br>Blockers                                       | Norvasc, Plendil,<br>Cardene, Adalat,<br>Procardia, Cardizem,<br>Calan | Hypertension                                |                                |                        | X                                    | ¥                 | For use as a single agent or in combination with other approved antihypertensive. DOWN for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DOWN period.  |
| Derm      | Calciprotriene<br>Ointment                                       | Dovonex  | Psoriasis                                   |                                | X                      |                                      |                   | DOWN until potential for idiosyncratic reaction has been ruled out.   |
| ENT       | Cetirizine   | Zyrtec   | Mild Allergic<br>Rhinitis                   |                                |                        | X                                    |                   | Minimum 72 hrs ground trial at initiation of therapy. Third line agent, trial of nasal steroid and Clartin/Allegra required first.  |
| Gen       | Chloroquine  | Aralen   | Malaria prophylaxis                         |                                | X                      |                                      |                   | Single dose ground trial required; 500 mg tablet (300 mg base) once weekly beginning 1-2 weeks prior to travel; ending 4 weeks after exposure (Reminder: last 2 weeks should be taken with primaquine).   |
| Dental    | Chlorhexadine<br>Gluconate                                       | Peridex  | Gingivitis                                  | X                              |                        |                                      |                   | DOWN not required unless condition interferes with duties.  |
| Gen       | Cholestyramine   | Questran   | Hyperlipidemia                              |                                | X                      |                                      |                   | DOWN until potential for idiosyncratic reaction has been ruled out.   |
| Derm      | Ciclopirox (Topical)   | Loprox   | Dermatomycoses,<br>seborrheic<br>dermatitis | X                              |                        |                                      |                   | DOWN not required unless condition or medication interferes with duties.  |
| Prophylax | Ciprofloxacin  | Cipro  | BW Prophylaxis                              |                                | X                      |                                      |                   | Ciprofloxacin may be used operationally after monitored ground trial (500 mg every 12 hours for 2 doses with 48 hrs DOWN documented in medical records) in event of BW incident for post-exposure treatment and prophylaxis for inhalational anthrax; Cipro Policy Letter.  |
| Psych     | Citalopram   | Celexa   | Waiverable Mental<br>Health Diagnoses       |                                |                        |                                      | X                 | Max dose 40 mg/day. Waiver will not be considered until member is on medication with stable dose and clinically asymptomatic for at least six months.   |
| GU        | Clomiphene   | Clomid   | Infertility                                 |                                | X                      |                                      |                   | DOWN until potential for idiosyncratic reaction has been ruled out.   |
| Gen       | Colestipol   | Colestid   | Hyperlipidemia                              |                                | X                      |                                      |                   | Minimum 7-day ground trial. A dose adjustment also requires a 7 day observation period.   |

| Category           | Medication   |  | Diagnosis   | No                             |                        | /N status<br>er Required)            | DOWN status                      |  |
|--------------------|--|--|---|--------------------------------|------------------------|--------------------------------------|----------------------------------|--|
| 5.00 <b>.3</b> 0.3 | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise)         | Trade Name (Not<br>Inclusive)  | or<br>Utilization   | DOWN<br>status<br>Or<br>Waiver | For<br>Ground<br>Trial | Symptoms Controlled (No Side Effect) | DOWN status<br>(Waiver Required) | Notes  |
| GU                 | Contraceptives (Implantable)   | Norplant, Implanon,<br>Mirena  | Contraception   |                                | X                      |                                      |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |
| GU                 | Contraceptives (Injectable)  | DepoProvera  | Contraception   |                                | X                      |                                      |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |
| GU                 | Contraceptives (Insertable)  | Nuvaring   | Contraception   |                                | X                      |                                      |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |
| GU                 | Contraceptives (Oral)  |  | Contraception   |                                | X                      |                                      |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |
| GU                 | Contraceptives<br>(Transdermal/<br>subdermal)                            |  | Contraception   |                                | X                      |                                      |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |
| ENT                | Cromolyn (Nasal)   | Crolom   | Mild Allergic, Non-<br>allergic, or<br>Vasomotor Rhinitis | X                              |                        |                                      |                                  | Underlying symptoms may require DOWN.  |
| Ophthal            | Cyclosporine Drops   | Restasis   |   |                                | X                      |                                      |                                  | Per MSD not disqualifying for GBO; underlying symptoms may require DOWN.   |
| Gen                | Dextroamphetamine/<br>Scopolamine  | Dex/Scop   | Airsickness   |                                | X                      |                                      |                                  | For airsickness during transport to launch facility.   |
| Gen                | Diclofenac Topical   | Voltaren   | Arthritis   | X                              |                        |                                      |                                  | Topical use approved for short term usage (less than 30 days) without a DOWN/waiver. Long term use would, or underlying condition might, require a waiver.   |
| Gen                | Dietary/ Herbal/<br>Nutritional<br>Supplements<br>Multivitamin<br>Folate |  | Wellness  | X                              |                        |                                      |                                  | Dietary, herbal, and nutritional supplements may generally be used by GBO personnel without Flight Surgeon approval, provided the product is used in accordance with manufacturers' directions for its intended use and not in violation of Air Force policy. GBO personnel are required to consult with the flight surgeon whenever the member experiences adverse reactions which may affect the member's ability to perform GBO.  Nutritional Supplement Policy Letter; Ephedra Policy Letter; SF 600 Overprint (optional tool for convenience) Human Performance Resource Center |
| Card               | Diuretics  | Chlorthalidone,<br>Hydrochlorothazide<br>or HCTZ in<br>combination with<br>triamterene | Hypertension  |                                |                        | X                                    |                                  | For use as a single agent or in combination with other approved antihypertensive. DOWN for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DOWN period.   |
| Card               | All other Diuretics or<br>Diuretic Combinations                          |  | Hypertension  |                                |                        |                                      | X                                | For use as a single agent or in combination with other approved antihypertensive. DOWN for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DOWN period.   |
| GU                 | Doxazosin Mesylate   | Cardura  | BPH Only  |                                |                        |                                      | X                                | Not to be used for HTN. Minimum 7-day ground trial. A dose adjustment also requires a 7 day DOWN period. Rapaflo is first line agent not requiring a waiver.   |

| Category   | Medic  | Medication                    |   | Diagnosis No                   |                        | N status<br>er Required)             | - DOWN status                    |  |
|------------|--|-------------------------------|---|--------------------------------|------------------------|--------------------------------------|----------------------------------|--|
| Category   | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise) | Trade Name (Not<br>Inclusive) | or<br>Utilization   | DOWN<br>status<br>Or<br>Waiver | For<br>Ground<br>Trial | Symptoms Controlled (No Side Effect) | DOWN status<br>(Waiver Required) | Notes  |
| Prophylax  | Doxycycline  | Vibramycin                    | BW Prophylaxis (2 <sup>nd</sup> Line)                               | X                              |                        |                                      |                                  | Should the individual develop an idiosyncratic reaction to Ciprofloxin; Doxycycline (100 mg, twice daily) is the recommended prophylaxis of choice (in the absence of contraindications).  |
| Prophylax  | Doxycycline  | Vibramycin                    | Malaria<br>Prophylaxis  | X                              |                        |                                      |                                  | 100 mg daily beginning 1-2 days prior to travel; ending 4 weeks after exposure (Reminder: last 2 weeks should be taken with primaquine)  |
| Prophylax  | Doxycycline  | Vibramycin                    | Prophylaxis<br>Against Diarrhea                                     | X                              |                        |                                      |                                  | 100 mg administered daily during period of exposure and for at least 2 days following exposure for prophylaxis against diarrhea in deployed personnel; total period of use not to exceed 2 weeks.  |
| GU         | Doxycycline  | Vibramycin                    | Suppressive Therapy for Chronic or Recurrent Prostatitis / Cystitis |                                |                        | X                                    |                                  | DOWN until potential for idiosyncratic reaction has been ruled out and control is maintained.  |
| Preventive | Emtricitabine/Tenofov<br>ir Disoproxil Fumarate                  | Truvada                       | HIV Pre-exposure<br>prophylaxis (PrEP)                              |                                |                        |                                      | X                                | Submit for waiver (to MAJCOM) after potential for idiosyncratic reaction has been ruled out and control is maintained, minimum of 30 days. Note, use of this medication for active HIV infection is not approved for aircrew. See <a href="Pre-Exposure Prophylaxis">Pre-Exposure Prophylaxis</a> (PrEP) waiver guide. |
| Preventive | Emtricitabine/Tenofov<br>ir Alafenamide                          | Descovy                       | HIV Pre-exposure<br>prophylaxis (PrEP)                              |                                |                        |                                      | Х                                | Submit for waiver (to MAJCOM) after potential for idiosyncratic reaction has been ruled out and control is maintained, minimum of 30 days. Note, use of this medication for active HIV infection is not approved for aircrew. See <a href="Pre-Exposure Prophylaxis">Pre-Exposure Prophylaxis</a> (PrEP) waiver guide. |
| Endo       | Eplerenon  | Inspra                        | Hyperaldosteronism  |                                |                        |                                      | X                                | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Eplerenone and Spironolactone Background Paper.   |
| Psych      | Escitalopram   | Lexapro                       | Waiverable Mental<br>Health Diagnoses                               |                                |                        |                                      | X                                | Max dose 20 mg/day waiver will not be considered until member is on medication with stable dose and clinically asymptomatic for at least six months.   |
| Endo       | Estrogen (Alone or with Progestin)                               |                               | Contraception/<br>Hormone<br>Replacement<br>Therapy                 |                                | X                      | X                                    |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |
| Endo       | Estrogen (Alone or<br>with Progestin)<br>(Topical)               |                               | Contraception/<br>Hormone<br>Replacement<br>Therapy                 |                                | X                      | X                                    |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |

| Category | Medic  | Medication  |  | Diagnosis No |                        | /N status<br>er Required)                     |                                  |  |
|----------|--|---|--|--------------|------------------------|---|----------------------------------|--|
| outage.  | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise)         | Trade Name (Not<br>Inclusive)   | or<br>Utilization                        |              | For<br>Ground<br>Trial | Symptoms<br>Controlled<br>(No Side<br>Effect) | DOWN status<br>(Waiver Required) | Notes  |
| Gen      | Etanercept   | Enbrel  | Rheumatological<br>Diseases              |              |                        |   | X                                | Restricted deployability. Requires IRILO/MEB prior to waiver submission. Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained.  Etanercept Background Paper   |
| Endo     | Etonogestrel/Ethinyl Estradiol (vaginal ring)                            | NuvaRing  | Contraception                            |              | X                      |   |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |
| Gen      | Ezetimibe  | Zetia   | Hyperlipidemia (2 <sup>nd</sup><br>Line) |              | X                      |   |                                  | DOWN for 3 days to rule out potential for idiosyncratic reaction; Ezetimibe Background Paper.  |
| Gen      | Ezetimibe/Simvastatin  | Vytorin   | Hyperlipidemia                           |              | X                      |   |                                  | DOWN for 3 days to rule out potential for idiosyncratic reaction; Ezetimibe Background Paper.  |
| Gen      | Fenofibrate  | Tricor  | Hyperlipidemia                           |              | X                      |   |                                  | Minimum of 7-days ground trial is required. Changes of dosage or preparation requires an additional 7-day DOWN period.   |
| Gen      | Ferrous Sulfate  |   | Iron Deficiency<br>Anemia                | X            |                        |   |                                  | Underlying conditions or symptoms may require waiver.  |
| ENT      | Fexofenadine   | Allegra   | Mild Allergic<br>Rhinitis                |              |                        | X   |                                  | Minimum 72 hrs ground trial at initiation of therapy and adequate control of symptoms.   |
| GU       | Finasteride  | Proscar   | Benign Prostatic<br>Hyperplasia          |              | X                      |   |                                  | DOWN until potential for idiosyncratic reaction has been ruled out (minimum 3 days).  Underlying conditions or symptoms may require waiver.  |
| GU       | Finasteride (1mg)  | Propecia  | Hair Loss                                |              | X                      |   |                                  | DOWN until potential for idiosyncratic reaction has been ruled out (minimum 3 days).  DoD policy prohibits purchase of this drug for treatment hair loss using DoD funds (see Finasteride Background Paper).   |
| Derm     | Fluconazole  | Diflucan  | Fungal infection                         |              | X                      |   |                                  |  |
| Ophth    | Fluoromethalone (and prednisolone, difluprednate, loteprednol etabonate) |   | Anti-Inflammatory                        | X            |                        |   |                                  | All steroid drops used to treat inflammation after approved CRS are not DOWNing in and of themselves. Underlying condition requiring use of steroid drops, including CRS, may require DOWN. See CRS Waiver Guide for information about DOWN time period after CRS. |
| GI       | Folate   |   | Sprue                                    |              |                        |   | X                                | DOWN until potential for idiosyncratic reaction has been ruled out and control is maintained, then submit for waiver.  |
| Psych    | Fluoxetine   | Prozac  | Waiverable Mental<br>Health Diagnoses    |              |                        |   | X                                | Max dose 80 mg/day. Waiver will not be considered until member is asymptomatic and shows clinical stability. ACS review is encouraged and MAJCOM dispositions waiver   |
| Gen      | Gemfibrozil  | Lopid   | Hyperlipidemia                           |              | X                      |   |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |
| GI       | H-2 Blockers and PPI's   | Aciphex, Nexium,<br>Pepcid, Prevacid,<br>Prilosec, Protonix,<br>Tagamet, Zantac | GERD                                     |              |                        | X   |                                  | DOWN until potential for idiosyncratic reaction has been ruled out (minimum 3 days) and symptoms controlled.   |

| Category | Medic  | ation  | Diagnosis No  |      |                        | N status<br>er Required)                      |                                  |  |
|----------|--|--|---|------|------------------------|---|----------------------------------|--|
| Category | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise) | Trade Name (Not<br>Inclusive)  | or<br>Utilization   | DOWN | For<br>Ground<br>Trial | Symptoms<br>Controlled<br>(No Side<br>Effect) | DOWN status<br>(Waiver Required) | Notes  |
| GI       | H-2 Blockers and PPI's   | Aciphex, Nexium, Pepcid, Prevacid, Prilosec, Protonix, Tagamet, Zantac | PUD   |      |                        |   | X                                | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained.   |
| GI       | Hemorrhoidal suppository   |  | Hemorrhoids   |      |                        | X   |                                  | DOWN is not required once symptoms relieved.   |
| Gen      | Hyaluronate<br>Derivatives                                       | Synvisc, Synvisc-<br>One, Euflexxa,<br>Hyalgan,<br>Orthovisc           | Osteoarthritis pain   |      |                        | X   |                                  | For intra-articular injection only. 48hrs post-injection DOWN required. Use of this medication does not require waiver; however, depending on severity, underlying condition MAY require waiver.   |
| Gen      | Hydrochlorothiazide  | Hydrodiuril  | Urolithiasis  |      |                        |   | X                                | For urolithiasis: either alone or in combination with allopurinol or oral potassium supplements. Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained.  |
| Gen      | Hydroxychloroquine   | Plaquenil  | Arthritis   |      |                        |   | X                                | DOWN until potential for idiosyncratic reaction has been ruled out and control is maintained, then submit for waiver.  |
| Derm     | Imiquimod (Topical)  | Aldara, Zyclara  | Warts, actinic<br>keratosis, basal cell<br>cancer                     | X    |                        |   |                                  | DOWN not required unless condition or medication interferes with life support gear or flying duties. Localized inflammatory reactions at the site of application are common, and should be considered prior to initiation of therapy.  |
| Immuno   | Immunization   |  | Wellness  | X    |                        |   |                                  | Adverse reactions are rare. Access to medical care on the ground is recommended for a period of 4 hours for all personnel, unless operational needs dictate otherwise. Recommend timing live immunizations such that side effects, if present, will have minimal operational impact. This guidance also applies to JEV (IXIARO). |
| Immuno   | Immunotherapy  |  | Allergy   |      | X                      |   |                                  | A 4-hour verbal DOWN is required after each injection;<br>GBO crew will not deploy on immunotherapy.   |
| Gen      | Infliximab   | Remicade   | Ankylosing<br>spondylitits,<br>psoriatic arthritis,<br>IBD, psoriasis |      |                        |   | X                                | No initial GBO waivers. Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Psoriasis when other medications have failed. Consult Waiver Guide for use in IBD patients.  Restricted deployability, see Waiver Guide. See Infliximab (Remicade) background paper           |
| Pulm     | INH-Rifapentine  | Priftin  | Latent TB   |      |                        |   | X                                | Directly Observed Therapy regimens only, IAW CDC/IDSA recommendations. Prior to deployment ensure PH clearance for completion of DOT.  |
| Pulm     | Ipratropium  | Atrovent   | Asthma  |      |                        |   | X                                | Requires IRILO/MEB submission prior to waiver.   |
| ENT      | Ipratropium nasal  | Atrovent nasal   | Allergic/non-<br>allergic rhinitis                                    |      | X                      |   |                                  | Minimum 7-day ground trial. A dose adjustment also requires a 7 day observation period.  |
| Pulm     | Isoniazid (INH)  | Nydrazid   | TB Prophylaxis  |      | X                      |   |                                  | For tuberculin converters who do not have active TB;<br>Minimum 72 hrs ground trial.   |

| Category | Medic  | ation                         | Diagnosis No or DOWN Utilization status Or Waiver |                      | N status<br>er Required) | DOWN status                          |                                  |  |
|----------|--|-------------------------------|---|----------------------|--------------------------|--------------------------------------|----------------------------------|--|
| Category | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise)   | Trade Name (Not<br>Inclusive) |   | DOWN<br>status<br>Or | For<br>Ground<br>Trial   | Symptoms Controlled (No Side Effect) | DOWN status<br>(Waiver Required) | Notes  |
| Derm     | Isotretinoin   | Acutane                       | Severe Acne                                       |                      | X                        |                                      |                                  | Minimum 2 week ground trial to ensure tolerance of the medication. See Acne Waiver Guide for full details.   |
| Gen      | Ketamine   | Ketalar                       | Anesthesia  |                      |                          | X                                    |                                  | Minimum 48hr DOWN required. Counsel members prior to elective dental or surgical procedures to request a alternate anesthetic.   |
| Ophth    | Ketotifen  | Zaditor                       | Itching and redness in the eyes due to allergies  |                      |                          | X                                    |                                  |  |
| Ophthal  | Latanoprost Drops  | Xalatan                       | Glaucoma  |                      |                          | X                                    |                                  | DOWN until potential for idiosyncratic reaction has been ruled out. Underlying condition may require waiver in which case, DOWN until waiver approved.   |
| Ophthal  | Levobunolol Drops  | Betagan                       | Glaucoma  |                      |                          | X                                    |                                  | DOWN until potential for idiosyncratic reaction has been ruled out. Underlying condition may require waiver in which case, DOWN until waiver approved.   |
| Pulm     | Levalbuterol   | Xopenex                       | Asthma  |                      |                          |                                      | X                                | DOWN until potential for idiosyncratic reaction has been ruled out and control is maintained, then submit for waiver. Requires MEB submission prior to waiver.   |
| Gen      | Levothyroxine  | Synthroid                     | Hypothyroidism or<br>Thyroid<br>Suppression       |                      |                          | X                                    |                                  | DOWN until potential for idiosyncratic reaction has been ruled out and all symptoms resolved. IRILO and waiver required if hypothyroidism is due the thyroid cancer treatment.   |
| ENT      | Loratadine   | Claritin                      | Allergy   |                      |                          | X                                    |                                  | Minimum 72 hrs ground trial at initiation of therapy and symptoms controlled. Maximum dosage is limited to 10 mg per day.  |
| Gen      | Melatonin  | Melatonin                     | Circadian Rhythm<br>Disorders                     |                      | X                        |                                      |                                  | Approved for use in all classes to be used for <u>Circadian</u> Rhythm Disorders (eg shift work changes, time zone changes) only. May only be used at physiologic doses not to exceed 5 mg/dose. Melatonin used may only be from <u>USP</u> verified formulation with NDC number to be ordered by TRICARE Prime vendor/pharmacy. May not be used for primary insomnia. |
| Gen      | Mesalamine<br>(complexed with<br>methyl/methacrylic<br>acid resin) | Asacol                        | Inflammatory<br>Bowel Disorder                    |                      |                          |                                      | X                                | DOWN until symptoms are controlled and minimum observation period is met for level of disease (see AMCB Minutes Paragraph 4g), then submit for waiver.   |
| Gen      | Mesalamine (delayed release via polymer)                           | Lialda                        | Inflammatory<br>Bowel Disorder                    |                      |                          |                                      | X                                | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. See Waiver Guide.   |
| Gen      | Mesalamine<br>(complexed with ethyl<br>cellulose)                  | Pentasa                       | Inflammatory<br>Bowel Disorder                    |                      |                          |                                      | X                                | DOWN until symptoms are controlled and minimum observation period is met for level of disease (see AMCB Minutes Paragraph 4g), then submit for waiver.   |
| Gen      | Mesalamine<br>(enema/ suppositories)                               | Rowasa                        | Inflammatory<br>Bowel Disorder                    |                      |                          |                                      | X                                | DOWN until symptoms are controlled and minimum observation period is met for level of disease (see AMCB Minutes Paragraph 4g), then submit for waiver.   |

| Category | Medication   |  | Diagnosis No   |                                | DOWN status<br>(No Waiver Required) |   | - DOWN status     |  |
|----------|--|--|--|--------------------------------|-------------------------------------|---|-------------------|--|
| Category | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise) | Trade Name (Not<br>Inclusive)  | or<br>Utilization  | DOWN<br>status<br>Or<br>Waiver | For<br>Ground<br>Trial              | Symptoms<br>Controlled<br>(No Side<br>Effect) | (Waiver Required) | Notes  |
| Endo     | Metformin  | Glucophage   | Diabetes Mellitus,<br>pre-diabetes<br>(includes impaired<br>fasting glucose) |                                |                                     |   | X                 | Submit for waiver after patient has been on medication for at least 30 days and the requirements for waiver submission (as defined by the Diabetes Waiver Guide) have been met.  |
| GU       | Metformin  | Glucophage   | Polycystic Ovarian<br>Syndrome   |                                |                                     | X   |                   | DOWN until potential for idiosyncratic reaction has been ruled out and symptoms are well controlled.   |
| Derm     | Metronidazole<br>(Topical)                                       | Flagyl   | Rosacea  | X                              |                                     |   |                   | DOWN not required unless condition or medication interferes with duties.   |
| GU       | Metronidazole<br>(Topical)                                       | Flagyl   | Vaginitis  | X                              |                                     |   |                   | DOWN is not required for occasional OTC use to provide<br>relief from minor self-limiting conditions unless underlying<br>condition is symptomatic and interferes with duties.   |
| Derm     | Minoxidil (Topical)  | Rogaine  | Hair loss  | X                              |                                     |   |                   | Topical use only.  |
| ENT      | Montelukast  | Singulair  | Allergic Rhinitis<br>Urticaria   |                                |                                     | X   |                   | Third line agent after non-sedating antihistamines and nasal steroid spray. DOWN until potential for idiosyncratic reaction has been ruled out and control is maintained.  |
| ENT      | Montelukast  | Singulair  | Asthma, broncho-<br>constriction   |                                |                                     |   | X                 | IRILO/MEB required for asthma, then submit waiver.   |
| Gen      | Nicotine Gum   | Nicorette  | Tobacco Addiction  | X                              |                                     |   |                   |  |
| Gen      | Nicotine Inhaler   | Nicotrol   | Tobacco<br>Addiction   | X                              |                                     |   |                   |  |
| Gen      | Nicotine Patch   | NicoDerm   | Tobacco Addiction  | X                              |                                     |   |                   |  |
| Gen      | Nifedipine Coat Core<br>Nifedipine GITS                          | Adalat CC<br>Procardia XL  | Hypertension   |                                |                                     |   | X                 | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Minimum 7-day observation after last dose adjustment.  NOTE: NO OTHER FORMULATIONS OF NIFEDIPINE ARE COVERED UNDER THIS POLICY. Nifedipine Background Paper |
| Gen      | NSAIDs (not Toradol)   | Celebrex, Daypro,<br>Indocin, Lodine,<br>Mobic, Motrin,<br>Relafen, Voltaren | Pain<br>(chronic use)  |                                |                                     | Х   |                   | DOWN until potential for idiosyncratic reaction has been ruled out and pain/inflammation control is achieved.  Consider underlying condition and potential for distraction due to pain. Celebrex Background Paper  Mobic Background Paper                              |
| Gen      | NSAIDs (not Toradol)   | Same as for Chronic pain   | Pain (acute use)   | X                              |                                     |   |                   | DOWN is not required for occasional (not regularly scheduled) use to provide relief from <b>minor</b> self-limiting conditions.  |
| Ophthal  | Olopatadine Eye<br>Drops   | Patanol  | Allergic<br>Conjunctivitis   |                                |                                     | X   |                   | Do not prescribe if member uses contact lenses. DOWN until potential for idiosyncratic reaction has been ruled out (minimum 3 days) and symptom control is maintained.   |
| Gen      | Oseltamivir  | Tamiflu  | Influenza<br>Prophylaxis<br>(2 <sup>nd</sup> Line)                           |                                | X                                   |   |                   | For unvaccinated personnel during community outbreaks or mission essential operations IAW MAJCOM policy; Requires 1-day ground trial; Oseltamivir Background Paper   |
| Gen      | Oseltamivir  | Tamiflu  | Influenza<br>Treatment   |                                |                                     | X   |                   | DOWN until the potential for idiosyncratic reaction has been ruled out and underlying condition does not interfere with duties; Oseltamivir Background Paper   |

| Category | Medic  | Medication                        |  | Diagnosis No                   |                        | /N status<br>er Required)            | DOWN status                      |  |
|----------|--|-----------------------------------|--|--------------------------------|------------------------|--------------------------------------|----------------------------------|--|
| outago.j | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise) | Trade Name (Not<br>Inclusive)     | or<br>Utilization                                | DOWN<br>status<br>Or<br>Waiver | For<br>Ground<br>Trial | Symptoms Controlled (No Side Effect) | DOWN status<br>(Waiver Required) | Notes  |
| Derm     | Pediculicide/<br>Scabicide                                       | Elimite, Eurax,<br>Lindane cream  | Scabies  |                                |                        | X                                    |                                  | DOWN until the potential for idiosyncratic reaction has been ruled out and underlying condition does not interfere with duties.  |
| GU       | Phenazopyridine  | Pyridium                          | UTI  | X                              |                        |                                      |                                  |  |
| Derm     | Pimecrolimus<br>1% Cream<br>(Topical)                            | Elidel                            | Atopic Dermatitis                                | X                              |                        |                                      |                                  | DOWN not required unless condition or medication interferes with duties Pimecrolimus Background Paper.   |
| Derm     | Podofilox<br>(Topical)   | Condylox                          | Warts  | X                              |                        |                                      |                                  | DOWN not required unless condition or medication interferes with duties.   |
| GU       | Potassium Citrate  | Urocit-K                          | Urolithiasis                                     |                                |                        |                                      | X                                | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Minimum 7-day observation after last dose adjustment.   |
| Gen      | Primaquine   | Primaquine                        | Malaria<br>Prophylaxis<br>(Terminal Phase)       |                                | X                      |                                      |                                  | Single dose ground trial required; 30 mg (base) daily (recommendation for increase from 15 mg to 30 mg by CDC) for terminal 14 days of post-exposure prophylaxis; Contraindication: G-6-PD deficiency, pregnancy, and possibly lactation (if infant has G-6-PD deficiency)                             |
| MS       | Probenecid   | Benemid                           | Gout or<br>Hyperuricemia                         |                                |                        | X                                    |                                  | Alone or in combination with thiazide (hydrochlorothiazide or chlorothiazide); DOWN until potential for idiosyncratic reaction has been ruled out and control is maintained  |
| Gen      | Potassium Iodide   | Thyroshield,<br>ThyroSafe, Iostat | Radiation<br>chemoprophylaxis                    |                                | X                      |                                      |                                  | 8 hour ground trial prior to first expected use (as operations allow). Do not prescribe for Airmen with known iodine sensitivity, thyroiditis, goiter, hyperkalemia, or pregnancy. Do not ground test unless use is anticipated/directed by MAJCOM or COCOM. Document ground test in ASIMS.            |
| GU       | Progestin (Injectable)   | Depo-<br>Provera/Norplant         | Contraception                                    |                                | X                      |                                      |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |
| GU       | Progestin (Implantable<br>Timed Released)                        | Mirena                            | Contraception                                    |                                | X                      |                                      |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.  |
| Gen      | Proguanil/<br>Atovaquone<br>(Combination)                        | Malarone                          | Malaria<br>Prophylaxis (2 <sup>nd</sup><br>Line) |                                | X                      |                                      |                                  | Single dose ground trial required; Malarone (250 mg atovaquone/100 mg proguanil) daily beginning 1-2 days prior to travel; ending 7 days after exposure (Reminder: last 7 days of Malarone should be taken with primaquine followed by another 7 days of primaquine alone);  Malarone Background Paper |
| Neuro    | Pyridostigmine   | Mestinon                          | CW Prophylaxis                                   |                                | X                      |                                      |                                  | DOWN until potential idiosyncratic reactions has been ruled out; Use IAW with operational guidance; Single dose ground trial advised.  |
| Onc      | Raloxifene   | Evista                            | Breast Cancer<br>prophylaxis                     |                                |                        |                                      | X                                | Use for breast cancer chemoprophylaxis in coordination with a specialist experienced in breast cancer chemoprophylaxis only. All other uses require review on case-by-case basis. Submit for waiver after at least 1 month and stable on therapy. See Raloxifene Paper.                                |

| Category | Medication   |  | Diagnosis  | No                             |                        | N status<br>er Required)                      |                                  |   |
|----------|--|--|--|--------------------------------|------------------------|---|----------------------------------|---|
| Category | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise)       | Trade Name (Not<br>Inclusive)  | or<br>Utilization                                    | DOWN<br>status<br>Or<br>Waiver | For<br>Ground<br>Trial | Symptoms<br>Controlled<br>(No Side<br>Effect) | DOWN status<br>(Waiver Required) | Notes   |
| Gen      | Resin Binding Agent  |  | Hyperlipidemia                                       |                                | X                      |   |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.   |
| Pulm     | Rifampin   |  | TB Prophylaxis                                       |                                | X                      |   |                                  | For tuberculin converters who do not have active TB, minimum 72 hours ground trial.   |
| Neuro    | Ropinirole   | Requip   | Restless Legs<br>Syndrome                            |                                |                        |   | X                                | DOWN for first 30 days of use (minimum).  |
| Gen      | Scopolamine/<br>Dextroamphetamine                                      | Scop/Dex   | Airsickness  |                                |                        | X   |                                  | Alone or in combination with dextroamphetamine for airsickness during transport to launch facility.   |
| Psych    | Sertraline   | Zoloft   | Waiverable Mental<br>Health Diagnoses                |                                |                        |   | X                                | Max dose 200 mg/day. Waiver will not be considered until member is on medication with stable dose and clinically asymptomatic for at least six months.  |
| GU       | Sildenafil   | Viagra   | Erectile<br>Dysfunction                              |                                | X                      |   |                                  | 24 hours grounding required after each dosage (Verbal DOWN acceptable). Not authorized for daily use.   |
| GU       | Silodosin  | Rapaflo  | ВРН  |                                |                        | X   |                                  | Maximum dose 8 mg daily. See <u>Silodosin Paper</u> . First line agent for BPH. No waiver required.   |
| Gen      | Spironolactone   | Aldactone  | Hirsutism,<br>Hyperaldosteronism<br>(2nd line)       |                                |                        |   | X                                | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Eplerenone and Spironolactone Background Paper.  |
| Gen      | Statin Derivatives   | Simvastatin,<br>Pravastatin,<br>Lovastatin,<br>Rosuvastatin,<br>Atorvastatin | Hyperlipidemia                                       |                                | X                      |   |                                  | Waiver not required if on single approved statin medication for hyperlipidemia. Approved medications include simvastatin, pravastatin, lovastatin and rosuvastatin up to 40 mg/day and atorvastatin up to 80 mg/day. Higher doses or combination of medication requires waiver. Requires at least 5 day ground trail when starting medication or for any adjustments to dosage to rule out idiosyncratic reactions. Follow up of lipids and LFTs should conform to accepted practice standards. |
| Pulm     | Steroids<br>(Inhaled orally)   |  | Asthma   |                                |                        |   | X                                | All inhaled corticosteroids approved for use in asthma by the FDA as of 13 May 2012 may be used. Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Requires IRILO/MEB submission prior to waiver.  |
| Pulm     | Long acting beta<br>agonist + inhaled<br>corticosteroid<br>combination | Advair<br>Dulera   | Asthma   |                                |                        |   | X                                | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Requires IRILO/MEB submission prior to waiver.   |
| GI       | Steroids<br>(metered-dose inhaler)                                     |  | Eosinophilic<br>Esophagitis                          |                                |                        |   | X                                | Topical corticosteroid therapy, administered via metered-<br>dose inhaler (swallowed), is approved for treatment of<br>eosinophilic esophagitis. Submit for waiver after potential<br>for idiosyncratic reaction has been ruled out and control is<br>maintained – see <u>EoE Waiver Guide</u> .  |
| ENT      | Steroids<br>(Nasal)  |  | Allergic rhinitis,<br>non-allergic nasal<br>symptoms |                                |                        | X   |                                  | DOWN until potential for idiosyncratic reaction has been ruled out and control is maintained.   |

| Category | Medication   |                               | Diagnosis   | No                             | DOWN status<br>( <u>No</u> Waiver Required) |                                      | 2000                             |  |
|----------|--|-------------------------------|---|--------------------------------|---|--------------------------------------|----------------------------------|--|
|          | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise) | Trade Name (Not<br>Inclusive) | or<br>Utilization                                     | DOWN<br>status<br>Or<br>Waiver | For<br>Ground<br>Trial                      | Symptoms Controlled (No Side Effect) | DOWN status<br>(Waiver Required) | Notes  |
| Derm     | Steroids<br>(Topical)  |                               | Rash or Skin<br>Diseases                              | X                              |   |                                      |                                  | DOWN not required unless condition or medication interferes with duties. If used for a chronic condition, the underlying diagnosis may require a waiver.   |
| GI       | Sucralfate   | Carafate                      | Prevention of Recurrent, Uncomplicated Duodenal Ulcer |                                |   | X                                    |                                  | 1 gram once daily; DOWN until potential for idiosyncratic reaction has been ruled out and control is maintained.   |
| Rheum    | Sulfasalazine  | Azulfidine                    | Reactive Arthritis<br>Rheumatoid<br>Arthritis         |                                |   |                                      | X                                | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Only authorized for RA cases that show no progression of disease (only 10% of cases). Mesalamine is better choice for inflammatory bowel disease control. Requires IRILO/MEB.   |
| Derm     | Tacrolimus<br>0.1% Cream<br>(Topical)                            | Protopic                      | Atopic Dermatitis                                     | X                              |   |                                      |                                  | DOWN not required unless condition or medication interferes with duties  |
| GU       | Tadalafil  | Cialis                        | Erectile<br>Dysfunction                               |                                | X   |                                      |                                  | 24 hours grounding required after each dosage (Verbal DOWN acceptable). Not authorized for daily use.  |
| GU       | Tamsulosin   | Flomax                        | ВРН   |                                |   |                                      | X                                | Minimum 7-day ground trial. A dose adjustment also requires a 7 day observation period. Repaflo is first line agent not requiring waiver.  |
| Derm     | Tazarotene 0.1% Gel<br>(topical)                                 | Tazorac                       | Acne Vulgaris   |                                | X   |                                      |                                  | Tazarotene Background Paper  |
| Derm     | Tazarotene 0.05% and 0.1% Gel (Topical)                          | Tazorac                       | Psoriasis   |                                | X   |                                      |                                  | Tazarotene Background Paper  |
| Derm     | Terbinafine  | Lamisil                       | Fungal Infection                                      |                                | X   |                                      |                                  | For treatment of fungal culture or formal histopathologically confirmed fungal infections only (positive KOH is <u>not</u> acceptable); DOWN for 72 hrs ground trial and obtain baseline LFTs; 250 mg daily for 12 weeks; <u>Terbinafine Background Paper</u> .  |
| GU       | Testosterone and<br>Estrogen<br>(combination)                    | Estratest                     | Hormone<br>Replacement<br>Therapy<br>(menopause)      |                                |   | X                                    |                                  | Minimum of 7-days ground trial is required; changes of dosages and/or preparation requires an additional 7-day observation period.   |
| GU       | Testosterone<br>(Injectable)                                     |                               | Hormone<br>Replacement<br>Therapy                     |                                |   |                                      | X                                | Appropriate urological work-up is required prior to starting medication. Minimum of 7-days ground trial, control of manifested symptoms are maintained, requires IRILO/MEB prior to waiver approval, then submit for waiver. A change of dosages and/or preparation requires an additional 7-day observation period. (Note: Testosterone has been classified as a Schedule 3 Controlled Drug.) |

| Category | Medication   |                               | Diagnosis   | No                             | DOWN status<br>( <u>No</u> Waiver Required) |                                      |                                  |   |
|----------|--|-------------------------------|---|--------------------------------|---|--------------------------------------|----------------------------------|---|
|          | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise) | Trade Name (Not<br>Inclusive) | or<br>Utilization   | DOWN<br>status<br>Or<br>Waiver | For<br>Ground<br>Trial                      | Symptoms Controlled (No Side Effect) | DOWN status<br>(Waiver Required) | Notes   |
| GU       | Testosterone<br>(Transdermal)                                    |                               | Hormone<br>Replacement<br>Therapy   |                                |   |                                      | X                                | Appropriate urological work-up is required prior to starting medication. Minimum of 7-days ground trial, control of manifested symptoms are maintained, requires IRILO/MEB prior to waiver approval, then submit for waiver. A change of dosages and/or preparation requires an additional 7-day observation period. (Note: Testosterone has been classified as a Schedule 3 Controlled Drug) |
| Derm     | Tetracycline   | Sumycin                       | Acne  |                                | X   |                                      |                                  | DOWN until potential for idiosyncratic reaction has been ruled out and control is maintained.   |
| GU       | Tetracycline   | Sumycin                       | Suppressive<br>Therapy for<br>Chronic or<br>Recurrent<br>Prostatitis / Cystitis |                                |   | X                                    |                                  | DOWN until potential for idiosyncratic reaction has been ruled out and control is maintained.   |
| Ophthal  | Timolol Drops  | Timoptic                      | Glaucoma  |                                |   | X                                    |                                  | DOWN until potential for idiosyncratic reaction has been ruled out. Underlying condition may require waiver in which case, DOWN until waiver approved.  |
| Neuro    | Topiramate   | Topamax                       | Migraines (only)  |                                |   |                                      | X                                | DOWN for first 30 days of use (minimum) and control is maintained and no side effects, then submit for waiver   |
| Derm     | Tretinoin (Topical)  | Retin-A                       | Acne  | X                              |   |                                      |                                  | DOWN not required unless condition or medication interferes with duties.  |
| GU       | Trimethoprim-<br>Sulfamethoxazole<br>(TMP/SMX)                   | Bactrim<br>Septra             | Suppressive Therapy for Chronic or Recurrent Prostatitis / Cystitis             |                                |   | X                                    |                                  | DOWN until potential for idiosyncratic reaction has been ruled out and control is maintained, then submit for waiver.   |
| Neuro    | Triptan class of medicines                                       | Maxalt<br>Relpax<br>Imitrex   | Migraines   |                                |   |                                      | X                                | Non-injection formulations only. Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Efficacy and tolerance of triptan on at least 2 migraine episodes must be documented. See Headache Waiver Guide for additional details.   |
| Derm     | Valacyclovir   | Valtrex                       | HSV Suppression   |                                | X   |                                      |                                  | DOWN until potential for idiosyncratic reaction has been ruled out.   |
| GU       | Vardenafil   | Levitra                       | Erectile<br>Dysfunction   |                                | X   |                                      |                                  | 24 hours grounding required after each dosage (Verbal DOWN acceptable). Not authorized for daily use.   |
| Gen      | Varenicline  | Chantix                       | Tobacco Cessation   |                                | X   |                                      |                                  | Two week ground trial to evaluate for irritability/aggression, attention deficit, SI/HI, seizure, sleep and any cardiac side effects. Encourage alcohol abstinence to prevent seizures and completion of 90 minute tobacco cessation (online or in person) program to maximize efficacy.  |

## Non-Waiverable Medications On This Page

|          | Medication  |                              | Diagnosis              | D  | No<br>OWN | DOWN<br>(No Waiver Required) |   |             | DOWN<br>(Waiver |                   | Notes   |
|----------|---|------------------------------|------------------------|----|-----------|------------------------------|---|-------------|-----------------|-------------------|---|
| Category | Generic Name (Oral<br>Preparation Unless<br>Specified Otherwise | Trade Name<br>(Not Inclusive | or<br>Utilization      | or | or Waiver | For<br>Ground<br>Trial       | Symptoms<br>Controlled<br>(No Side<br>Effect) |             | Required)       | Not<br>Waiverable |   |
| Gen      | Depo-Medrol   |                              | Allergy                |    |           |                              |   |             |                 | X                 | Conidition requiring injectable steroid is reasons for grounding.   |
| Gen      | Mefloquine  | Lariam                       | Malaria<br>Prophylaxis |    | N         | lot W                        | aiveral                                       | <b>ol</b> o | e               | X                 | Adverse effects include but not limited to: optic neuritis, cataracts, decreased night vision, blurred vision and photosensitivity, pseudotumor cerebri, depression, psychosis, and suicide |
| Derm     | Minocycline   | Minocin                      | Acne                   |    |           |                              |   |             |                 | X                 | Unacceptable (up to 70%) incidence of vestibular side-effects   |